Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-214 and Nivolumab in Advanced/Metastatic Sarcoma
NCT03282344Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2017
- Primary completion
- Sep 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of bempegaldesleukin in sarcoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Started Sep 2017; status: active, not recruiting.
02
Drugs
bempegaldesleukin
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT03282344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282344.